AEON Biopharma, Inc. issued and sold 4,696,102 shares of Class A common stock to underwriters following the partial exercise of an over-allotment option, generating approximately $1.5 million in gross proceeds and $1.4 million in net proceeds. This transaction follows a previously reported public offering completed on July 15, 2026. AEON Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions.
